A gallium(III) Schiff base-curcumin complex that binds to amyloid-β plaques

Area of Science:

• Radiochemistry
• Neuroscience
• Materials Science

Background:

• Alzheimer's disease is characterized by amyloid-beta (Aβ) plaque formation in the brain.
• Positron-emission tomography (PET) requires imaging agents capable of crossing the blood-brain barrier.
• Developing targeted PET agents for Aβ plaques is crucial for early Alzheimer's diagnosis.

Purpose of the Study:

• To synthesize a charge-neutral, low molecular weight, lipophilic gallium complex.
• To create a complex capable of crossing the blood-brain barrier and binding to Aβ plaques.
• To explore the potential of this complex as a precursor for Gallium-68 (⁶⁸Ga) based PET imaging agents.

Main Methods:

• A six-coordinate Ga³⁺ complex was synthesized using a tetradentate N₂O₂ Schiff base ligand and curcumin as a bidentate ligand.
• The Schiff base ligand adopted a cis-β configuration.
• The resulting complex was tested for its binding affinity to Aβ plaques in human brain tissue.

Main Results:

• A stable, six-coordinate gallium complex was successfully synthesized.
• The complex demonstrated binding to amyloid-beta plaques in human brain tissue.
• The chemical properties suggest potential for modification into a PET imaging agent.

Conclusions:

• The synthesized gallium complex shows potential for targeting amyloid-beta plaques.
• Further development using Gallium-68 could lead to novel PET imaging agents for Alzheimer's disease.
• This approach offers a new strategy for developing diagnostic tools for neurodegenerative diseases.